Get the Stockscreener App
1.95
0.52%
0.01
Artelo Biosciences Inc stock is traded at $1.95, with a volume of 307.96K.
It is up +0.52% in the last 24 hours and up +8.33% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.94
Open:
$2.03
24h Volume:
307.96K
Relative Volume:
0.58
Market Cap:
$3.94M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.6171
EPS:
-3.16
Net Cash Flow:
$-8.96M
1W Performance:
+5.98%
1M Performance:
+8.33%
6M Performance:
-72.48%
1Y Performance:
-70.45%
1-Day Range:
$1.8533
$2.08
1-Week Range:
$1.69
$2.08
52-Week Range:
$1.5206
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.95 | 3.92M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences, Inc. (ARTL) 6.68% in After-hours: Following Strong Business Update - Stocks Telegraph
Artelo Biosciences Inc Stock Analysis and ForecastMarket Sentiment Shifts & Superior Capital Growth - earlytimes.in
Is Artelo Biosciences Inc a good long term investmentEconomic Data Impact & High Profit Trading Signals - earlytimes.in
Artelo Biosciences Revises Bylaws, Alters Governance Structure - MSN
Artelo Biosciences (ARTL) Stock: Faces Market Reaction After Positive Research on Stress Relief Treatments - parameter.io
Unexpected Movements: Artelo Biosciences’ Stock Dynamics - timothysykes.com
Artelo Biosciences (ARTL) Research Highlights Potential of FABP5 Inhibitor in Stress Management - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of A Novel Fatty Acid Binding Protein 5 Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Mod - marketscreener.com
Artelo Biosciences, Inc. (ARTL) -5.56% in After-hours: Stock Declines Amid Routine Trading - Stocks Telegraph
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Will Artelo Biosciences Inc. stock see insider buyingJobs Report & AI Driven Stock Movement Reports - Newser
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
What analysts say about Artelo Biosciences Inc stockMACD Histogram Signals & Target Triple-Digit Stock Opportunities - earlytimes.in
Artelo Biosciences Appeals Nasdaq Delisting Decision - MSN
Why Artelo Biosciences Inc. stock is favored by top institutionsJuly 2025 Drop Watch & Safe Capital Growth Trade Ideas - moha.gov.vn
Artelo Biosciences (NASDAQ:ARTL) Given “Hold” Rating at Maxim Group - Defense World
Artelo Biosciences Inc. stock trend forecast2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Regression analysis insights on Artelo Biosciences Inc. performance - newser.com
Published on: 2025-11-19 14:48:52 - newser.com
Analyzing net buyer seller activity in Artelo Biosciences Inc.2025 Analyst Calls & Real-Time Chart Breakout Alerts - newser.com
ARTL Stock Downgraded to Hold by Maxim Group | ARTL Stock News - GuruFocus
Applying Wyckoff theory to Artelo Biosciences Inc. stockMarket Performance Recap & Verified Technical Trade Signals - newser.com
Will Artelo Biosciences Inc. outperform the marketQuarterly Trade Report & Growth Focused Entry Reports - newser.com
Maxim Downgrades Artelo Biosciences to Hold From Buy - MarketScreener
Published on: 2025-11-19 04:37:27 - newser.com
What is the fair value of Artelo Biosciences Inc. stock nowEarnings Risk Report & Fast Gain Swing Alerts - newser.com
Artelo Biosciences Reports Increased Losses Amid R&D Investments - TipRanks
Published on: 2025-11-17 02:33:09 - newser.com
Will Artelo Biosciences Inc. see short term momentumCEO Change & Free AI Powered Buy and Sell Recommendations - newser.com
Analyzing Artelo Biosciences Inc. with risk reward ratio chartsGap Up & Fast Entry Momentum Trade Alerts - newser.com
Measuring Artelo Biosciences Inc.’s beta against major indicesTrade Exit Summary & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-15 11:36:28 - newser.com
What momentum shifts mean for Artelo Biosciences Inc.Weekly Volume Report & Short-Term High Return Strategies - newser.com
Published on: 2025-11-14 04:04:42 - newser.com
Published on: 2025-11-14 02:11:25 - newser.com
Is Artelo Biosciences Inc. building a consolidation baseGold Moves & High Accuracy Trade Alerts - newser.com
Artelo Biosciences Reports Loss As R&D Spending Rises - Finimize
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):